Stem Cell Educator Therapy for Type 1 Diabetes
Trial Summary
Do I need to stop my current medications for the trial?
The trial requires that you stop using immunosuppressive medications at least one month before enrollment. Other medications are not specifically mentioned, so it's best to discuss with the trial team.
What data supports the idea that Stem Cell Educator Therapy for Type 1 Diabetes is an effective treatment?
The available research shows that Stem Cell Educator Therapy has been tested in international clinical trials and has demonstrated safety and effectiveness in treating Type 1 Diabetes. This treatment helps correct the immune system's attack on the body's own cells and supports the recovery of insulin-producing cells in the pancreas. Unlike other treatments, it does not have the safety and ethical concerns associated with traditional therapies. The therapy has shown potential to improve the body's ability to manage blood sugar levels, which is crucial for people with Type 1 Diabetes.12345
What safety data exists for Stem Cell Educator Therapy in treating Type 1 Diabetes?
Stem Cell Educator Therapy has been evaluated for over 10 years through international multi-center clinical studies, demonstrating its clinical safety and efficacy in treating Type 1 Diabetes and other autoimmune diseases. The therapy is based on immune education by cord-blood-derived multipotent stem cells and has shown potential to correct autoimmunity and restore beta cell function without the safety and ethical concerns associated with conventional therapies.12467
Is Stem Cell Educator Therapy a promising treatment for Type 1 Diabetes?
Yes, Stem Cell Educator Therapy is a promising treatment for Type 1 Diabetes. It uses special stem cells to help the immune system work better and restore the function of insulin-producing cells in the pancreas. Clinical trials have shown it to be safe and effective, offering hope for better management of the disease.12458
What is the purpose of this trial?
This trial uses Stem Cell Educator (SCE) therapy, which treats a patient's own blood cells with umbilical cord blood stem cells. It targets patients with Type 1 diabetes who need better treatment options. The therapy helps the immune system stop attacking the pancreas by 'educating' the immune cells. Stem Cell Educator therapy has been evaluated through international clinical studies, demonstrating its safety and efficacy in Type 1 diabetes and other autoimmune diseases.
Research Team
YONG ZHAO, MD,PhD
Principal Investigator
Throne Biotechnologies Inc.
Eligibility Criteria
This trial is for adults and children over 14 with Type 1 Diabetes, diagnosed within the last two years. Participants must have a certain level of C-peptide, use continuous glucose monitoring, consent to study requirements including birth control for women, and not be on immunosuppressants or have other autoimmune diseases.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive one treatment with Stem Cell Educator (SCE) therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment, including measurements of immune markers and glucose control
Treatment Details
Interventions
- Stem Cell Educator Therapy
Stem Cell Educator Therapy is already approved in China, United States for the following indications:
- Type 1 Diabetes
- Type 1 Diabetes
Find a Clinic Near You
Who Is Running the Clinical Trial?
Throne Biotechnologies Inc.
Lead Sponsor
Hackensack Meridian Health
Collaborator